References
1. Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for
Recurrent Squamous-Cell Carcinoma of the Head and Neck. The New
England journal of medicine . Nov 10 2016;375(19):1856-1867.
doi:10.1056/NEJMoa1602252
2. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis.Journal of the American Academy of Dermatology . Feb
2007;56(2):181-200. doi:10.1016/j.jaad.2006.04.048
3. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for
assessment of drug causality in Stevens-Johnson Syndrome and toxic
epidermal necrolysis: comparison with case-control analysis.Clinical pharmacology and therapeutics . Jul 2010;88(1):60-8.
doi:10.1038/clpt.2009.252
4. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival
analysis of a cohort of patients with Stevens-Johnson syndrome and toxic
epidermal necrolysis. The Journal of investigative dermatology .
May 2013;133(5):1197-204. doi:10.1038/jid.2012.510
5. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current
Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Clinical reviews in allergy & immunology . Feb
2018;54(1):147-176. doi:10.1007/s12016-017-8654-z
6. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell
death-ligand 1 expression in TEN associated with nivolumab therapy.Journal of cutaneous pathology . Apr 2017;44(4):381-384.
doi:10.1111/cup.12876
7. Salati M, Pifferi M, Baldessari C, et al. Stevens-Johnson syndrome
during nivolumab treatment of NSCLC. Annals of oncology : official
journal of the European Society for Medical Oncology . Jan 1
2018;29(1):283-284. doi:10.1093/annonc/mdx640
8. Griffin LL, Cove-Smith L, Alachkar H, Radford JA, Brooke R, Linton
KM. Toxic epidermal necrolysis (TEN) associated with the use of
nivolumab (PD-1 inhibitor) for lymphoma. JAAD case reports . Apr
2018;4(3):229-231. doi:10.1016/j.jdcr.2017.09.028
9. Dasanu CA. Late-onset Stevens-Johnson syndrome due to nivolumab use
for hepatocellular carcinoma. Journal of oncology pharmacy
practice : official publication of the International Society of Oncology
Pharmacy Practitioners . Feb 19 2019:1078155219830166.
doi:10.1177/1078155219830166
10. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or
Monotherapy in Untreated Melanoma. The New England journal of
medicine . Sep 24 2015;373(13):1270-1. doi:10.1056/NEJMc1509660